Dictionnaire de théologie morale... ; suivi d'un Plan méthodique de la théologie laissé inédit par Bergier et d'après lequel on peut lire avec suite son dictionnaire... : présentant un exposé complet de la morale chrétienne, contenant une règle de conduite pour les principales circonstances de la vie, offrant un complément nécessaire à toutes les éditions du Dictionnaire.... Tome 31 / par M. l'abbé Pierrot,...

Collection : Encyclopédie théologique ...

Planifier un sevrage aux glucocorticoïdes: stratégie diagnostique et thérapeutique [How to plan glucocorticoid withdrawal: diagnostic and therapeutic strategies]

Glucocorticoïds are widely used in medicine and associated with numerous complications. Whenever possible, dosage reduction or treatment withdrawal should be considered as soon as possible depending on the underlying disease being treated. Administration of glucocorticoids induces a physiologic negative feed-back on the hypothalamic-pituitary-adrenal (HPA) axis and three clinical situations can be distinguished during treatment withdrawal: reactivation of the disease for which the glucocorticoids were prescribed, acute adrenal insufficiency and steroid withdrawal syndrome. Acute adrenal insufficiency is a feared complication but probably rare. It is usually seen during stress situations and can be observed long after steroid withdrawal. There is no good predictive marker to anticipate acute adrenal insufficiency and clinical evaluation of the patient remains a key element in its diagnosis. If adrenal insufficiency is suspected, HPA suppression can be assessed with dynamic tests. During stress situation, steroid administration is then recommended depending on the severity of the stress.

4-7-19, stade Pershing, départ du marathon [modifié des Jeux interalliés, en tête n°1103 Auguste Broos et n°973 Carlo Speroni suivi par Fred Faller, puis n°846 Clyde Stout, à sa droite Jean Vermeulen, n°730 J. H. Massey, n°1189 Thomas Sinton Hewitt, n°971 Armando Pagliani, n°1280 Alphonse Van Hoey, n°972 Antenore Negri, n°1274 Jules Holsbeeke] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54713

Manuel pour l'analyse des substances organiques / par J. Liebig,... ; traduit de l'allemand par A.-J.-L. Jourdan. Suivi de l'examen critique des procédés et des résultats de l'analyse des corps organisés / par F. V. Raspail,...

Comprend : Examen critique des procédés et des résultats de l'analyse des corps organisés

Quelques mécanismes moléculaires impliqués dans la pathogenèse du diabète de type II et leur importance thérapeutique potentielle [Various molecular mechanisms involved in the pathogenesis of type II diabetes and their potential therapeutic importance]

The pancreatic beta cell presents functional abnormalities in the early stages of development of non-insulin dependent diabetes mellitus (NIDDM). The disappearance of the first phase of insulin secretion induced by a glucose load is a early marker of NIDDM. This abnormality could be secondary to the low expression of the pancreatic glucose transporter GLUT2. Together with the glucokinase enzyme, GLUT2 is responsible for proper beta cell sensing of the extracellular glucose levels. In NIDDM, the GLUT2 mRNA levels are low, a fact which suggests a transcriptional defect of the GLUT2 gene. The first phase of glucose-induced insulin secretion by the beta pancreatic cell can be partly restored by the administration of a peptide discovered by a molecular approach, the glucagon-like peptide 1 (GLP-1). The gene encoding for the glucagon is expressed in a cell-specific manner in the A cells of the pancreatic islet and the L cells of the intestinal tract. The maturation process of the propeptide encoded by the glucagon gene is different in the two cells: the glucagon is the main hormone produced by the A cells whereas the glucagon-like peptide 1 (GLP-1) is the major peptide synthesized by the L cells of the intestine. GLP-1 is an incretin hormone and is at present the most potent insulinotropic peptide. The first results of the administration of GLP-1 to normal volunteers and diabetic patients are promising and may be a new therapeutic approach to treating diabetic patients.